Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02255760 · ClinicalTrials.gov registry record · Phase 1
Phase 1 Randomized Double-blind Placebo Controlled Study to Evaluate Safety and PK of MEDI3902 in Healthy Adults
A Phase 1 study, sponsored by MedImmune.
- Completed
- Registry status
- Phase 1
- Development phase
- 56
- Enrollment target
NCT02255760 is a Phase 1 study that has completed, run by MedImmune. The registered enrollment target is 56 participants.
The verdict
NCT02255760, a Phase 1 study, has completed, sponsored by MedImmune.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 56 participants
- Enrollment target
Study Summary
This is a Phase 1, randomized, double-blind, placebo-controlled, dose escalation study evaluating the safety and tolerability of a single ascending IV dose of MEDI3902 in healthy adult subjects 18 to 60 years of age.
Interventions
- OTHER Placebo
- DRUG MEDI3902 - Dose 1
- DRUG MEDI3902 - Dose 2
- DRUG MEDI3902 - Dose 3
- DRUG MEDI3902 - Dose 4
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2014-09-04 |
| Est. Completion | 2015-04-20 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02255760
The ClinicalTrials.gov registry entry for NCT02255760 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MedImmune, which has 210 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT02255760 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02255760 about?
NCT02255760 is a clinical study titled "Phase 1 Randomized Double-blind Placebo Controlled Study to Evaluate Safety and PK of MEDI3902 in Healthy Adults". This is a Phase 1, randomized, double-blind, placebo-controlled, dose escalation study evaluating the safety and tolerability of a single ascending IV dose of MEDI3902 in healthy adult subjects 18 to 60 years of age.
What is the current status of trial NCT02255760?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 56 participants. The study started on 2014-09-04. Estimated completion is 2015-04-20.
What interventions are being tested in trial NCT02255760?
The interventions under investigation include: Placebo (OTHER), MEDI3902 - Dose 1 (DRUG), MEDI3902 - Dose 2 (DRUG), MEDI3902 - Dose 3 (DRUG), MEDI3902 - Dose 4 (DRUG).
Who is sponsoring clinical trial NCT02255760?
This trial is sponsored by MedImmune, which has 210 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.